CBS domains: Structure, function, and pathology in human proteins

American Journal of Physiology - Cell Physiology

Volumn 289, Issue 6 58-6, 2005, Pages

  Ignoul, Sofie ^a   Eggermont, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

AMP activated protein kinase; Chloride channel; Cystathionine synthase

Indexed keywords

ADENOSINE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; CELL PROTEIN; CHLORIDE CHANNEL; CYSTATHIONINE BETA SYNTHASE; DIMER; INOSINATE DEHYDROGENASE; MEMBRANE PROTEIN; PROTEOME; S ADENOSYLMETHIONINE;

CHANNEL GATING; CRYSTALLOGRAPHY; CYTOSOL; DIMERIZATION; GENETIC CONSERVATION; HOMOCYSTINURIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LIGAND BINDING; METABOLITE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN TARGETING; RETINITIS PIGMENTOSA; REVIEW; STRUCTURE ANALYSIS; TANDEM REPEAT; THOMSEN DISEASE;

ANIMALS; CHLORIDE CHANNELS; CYSTATHIONINE BETA-SYNTHASE; DIMERIZATION; GENETIC DISEASES, INBORN; HUMANS; IMP DEHYDROGENASE; MODELS, MOLECULAR; MULTIENZYME COMPLEXES; MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES;

ARCHAEA; BACTERIA (MICROORGANISMS); EUKARYOTA; PROKARYOTA;

EID: 27744463780     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00282.2005     Document Type: Review

References (79)

1. Allison AC, Hovi T, Watts RW, and Webster AD. Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet 2: 1179-1183, 1975.
2. Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, Kanter RJ, McGarry K, Seidman JG, and Seidman CE. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109: 357-362, 2002.
3. Bateman A. The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem Sci 22: 12-13, 1997.
4. 3a. Bennetts B, Rychkov GY, Ng HL, Morton CJ, Stapleton D, Parker MW, and Cromer BA. Cytoplasmic ATP-sensing domains regulate gating of skeletal muscle ClC-1 chloride channels. J Biol Chem 280: 32452-32458, 2005.
5. 2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 10: 1215-1220, 2001.
6. Bowne SJ, Sullivan LS, Blanton SH, Cepko CL, Blackshaw S, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, and Daiger SP. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum Mol Genet 11: 559-568, 2002.
7. Carr G, Simmons N, and Sayer J. A role for CBS domain 2 in trafficking of chloride channel CLC-5. Biochem Biophys Res Commun 310: 600-605, 2003.
8. Chen X, Jhee KH, and Kruger WD. Production of the neuromodulator H2S by cystathionine β-synthase via the condensation of cysteine and homocysteine. J Biol Chem 279: 52082-52086, 2004.
9. Cheung PC, Salt IP, Davies SP, Hardie DG, and Carling D. Characterization of AMP-activated protein kinase γ-subunit isoforms and their role in AMP binding. Biochem J 346: 659-669, 2000.
10. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, deVernejoul MC, and Van Hul W. Albers-Schonberg disease (autosomal dominant osteopetrosis, type 11) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10: 2861-2867, 2001.
11. Colby TD, Vanderveen K, Strickler MD, Markham GD, and Goldstein BM. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc Nutl Acad Sci USA 96: 3531-3536, 1999.
12. Collart FR and Huberman E. Cloning and sequence analysis of the human and Chinese hamster inosine-5′-monophosphate dehydrogenase cDNAs. J Biol Chem 263: 15769-15772, 1988.
13. Cooney DA, Wilson Y, and McGee E. A straightforward radiometric technique for measuring IMP dehydrogenase. Anal Biochem 130: 339-345, 1983.
14. Corton JM, Gillespie JG, Hawley SA, and Hardie DG. 5-Aminoimidazole-4- carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229: 558-565, 1995.
15. Crabtree GW and Henderson JF. Rate-limiting steps in the interconversion of purine ribonucleotides in Ehrlich ascites tumor cells in vitro. Cancer Res 31: 985-991, 1971.
16. 2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome. J Biol Chem 111: 51017-51024, 2002.
17. Dayton JS, Lindsten T, Thompson CB, and Mitchell BS. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunol 152: 984-991, 1994.
18. Dutzler R, Campbell EB, Cadene M, Chait BT, and MacKinnon R. X-ray structure of a ClC chloride channel at 3.0A reveals the molecular basis of anion selectivity. Nature 415: 287-294, 2002.
19. Estevez R, Pusch M, Ferrer-Costa C, Orozco M, and Jentsch TJ. Functional and structural conservation of CBS domains from CLC channels. J Physiol 557: 363-378, 2004.
20. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr 157, Suppl 2: S40-S44, 1998.
21. Finkelstein JD, Kyle WE, Martin JL, and Pick AM. Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. Biochem Biophys Res Commun 66: 81-87, 1975.
22. Fong P, Rehfeldt A, and Jentsch TJ. Determinants of slow gating in ClC-0, the voltage-gated chloride channel of torpedo marmorata. Am J Physiol Cell Physiol 274: C966-C973, 1998.
23. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R, and Hassan AS. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 344: 1823-1831, 2001.
24. Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, and Roberts R. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 104: 3030-3033, 2001.
25. Gu JJ, Stegmann S, Gathy K, Murray R, Laliberte J, Ayscue L, and Mitchell BS. Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. J Clin Invest 106: 599-606, 2000.
26. Gu JJ, Tolin AK, Jain J, Huang H, Santiago L, and Mitchell BS. Targeted disruption of the inosine 5′-monophosphate dehydrogenase type 1 gene in mice. Mol Cell Biol 23: 6702-6712, 2003.
27. 1 subunit of the AMP-activated protein kinase. FEBS Lett 500: 163-168, 2001.
28. Hardie DG and Hawley SA. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 23: 1112-1119, 2001.
29. Haug K, Warnstedt M, Alekov AK, Sander T, Ramirez A, Poser B, Maljevic S, Hebeisen S, Kubisch C, Rebstock J, Horvath S, Hallmann K, Dullinger JS, Rau B, Haverkamp F, Beyenburg S, Schulz H, Janz D, Giese B, Muller-Newen G, Propping P, Elger CE, Fahlke C, Lerche H, and Heils A. Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet 33: 527-532, 2003.
30. 2+/calmodulin activates the calmodulin-dependent protein kinase 1 cascade, via three independent mechanisms. J Biol Chem 270: 27186-27191, 1995.
31. Hebeisen S, Biela A, Giese B, Müller-Newen G, Hidalgo P, and Fahlke C. The role of the carboxy-terminus in ClC chloride channel function. J Biol Chem 279: 13140-13147, 2004.
32. Hryciw DH, Rychkov GY, Hughes BP, and Bretag AH. Relevance of the D13 region to the function of the skeletal muscle chloride channel, ClC-1. J Biol Chem 273: 4304-4307, 1998.
33. Jackson RC, Morris HP, and Weber G. Partial purification, properties and regulation of inosine 5′ phosphate dehydrogenase in normal and malignant rat tissues. Biochem J 166: 1-10, 1977.
34. Jackson RC, Weber G, and Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256: 331-333, 1975.
35. Jain J, Almquist SJ, Ford PJ, Shlyakhter D, Wang Y, Nimmesgern E, and Germann UA. Regulation of inosine monophosphate dehydrogenase type 1 and type II isoforms in human lymphocytes. Biochem Pharmacol 67: 767-776, 2004.
36. Janosik M, Kery V, Gaustadnes M, Maclean KN, and Kraus JP. Regulation of human cystathionine β-synthase by 5-adenosyl-L-methionine: evidence for two catalytically active conformations involving an autoinhibitory domain in the C-terminal region. Biochemistry 40: 10625-10633, 2001.
37. Jentsch TJ, Stein V, Weinreich F, and Zdebik AA. Molecular structure and physiological function of chloride channels. Physiol Rev 82: 503-568, 2002.
38. Jhee KH, McPhie P, and Miles EW. Domain architecture of the heme-independent yeast cystathionine β-synthase provides insights into mechanisms of catalysis and regulation. Biochemistry 39: 10548-10556, 2000.
39. Kennan A, Aherne A, Palfi A, Humphries M, McKee A, Stitt A, Simpson DA, Demtroder K, Orntoft T, Ayuso C, Kenna PF, Farrar GJ, and Humphries P. Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. Hum Mol Genet 11: 547-557, 2002.
40. Kery V, Poneleit L, and Kraus JP. Trypsin cleavage of human cystathionine β-synthase into an evolutionarily conserved active core: structural and functional consequences. Arch Biochem Biophys 355: 222-232, 1998.
41. Kluijtmans LA, Boers GH, Stevens EM, Renier WO, Kraus JP, Trijbels FJ, van den Heuvel LP, and Blom HJ. Defective cystathionine β-synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient. J Clin Invest 98: 285-289, 1996.
42. Konrad M, Vollmer M, Lemmink HH, van den Heuvel LP, Jeck N, Vargas-Poussou R, Lakings A, Ruf R, Deschenes G, Antignac C, Guay-Woodford L, Knoers NV, Seyberth HW, Feldmann D, and Hildebrandt F. Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J Am Soc Nephrol 11: 1449-1459, 2000.
43. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, and Jentsch TJ. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104: 205-215, 2001.
44. Kraus J, Packman S, Fowler B, and Rosenberg LE. Purification and properties of cystathionine β-synthase from human liver. Evidence for identical subunits. J Biol Chem 253: 6523-6528, 1978.
45. Kraus JP and Rosenberg LE. Cystathionine β-synthase from human liver: improved purification scheme and additional characterization of the enzyme in crude and pure form. Arch Biochem Biophys 222: 44-52, 1983.
46. Kruger WD and Cox DR. A yeast assay for functional detection of mutations in the human cystathionine β-synthase gene. Hum Mol Genet 4: 1155-1161, 1995.
47. Lloyd SE, Gunther W, Pearce SH, Thomson A, Bianchi ML, Bosio M, Craig IW, Fisher SE, Scheinman SJ, Wrong O, Jentsch TJ, and Thakker RV. Characterisation of renal chloride channel, CLCN5, mutations in hypercalciuric nephrolithiasis (kidney stones) disorders. Hum Mol Genet 6: 1233-1239, 1997.
48. Maclean KN, Janosik M, Oliveriusova J, Kery V, and Kraus JP. Transsulfuration in Saccharomyces cerevisiae is not dependent on heme: purification and characterization of recombinant yeast cystathionine -synthase. J Inorg Biochem 81: 161-171, 2000.
49. Maduke M, Pheasant DJ, and Miller C. High-level expression, functional reconstitution, and quaternary structure of a prokaryotic ClC-type chloride channel. J Gen Physiol 114: 713-722, 1999.
50. Maduke M, Williams C, and Miller C. Formation of CLC-0 chloride channels from separated transmembrane and cytoplasmic domains. Biochemistry 37: 1315-1321, 1998.
51. Meier M, Janosik M, Kery V, Kraus JP, and Burkhard P. Structure of human cystathionine β-synthase: a unique pyridoxal 5′-phosphate-dependent heme protein. EMBO J 20: 3910-3916, 2001.
52. Milan D, Jeon JT, Looft C, Amarger V, Robic A, Thelander M, Rogel-Gaillard C, Paul S, Iannuccelli N, Rask L, Ronne H, Lundstrom K, Reinsch N, Gellin J, Kalm E, Roy PL, Chardon P, and Andersson L. A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. Science 288: 1248-1251, 2000.
53. Miles EW and Kraus JP. Cystathionine β-synthase: structure, function, regulation and location of homocystinuria-causing mutations. J Biol Chem 279: 29871-29874, 2004.
54. Miller MD, Schwarzenbacher R, von Delft F, Abdubek P, Ambing E, Biorac T, Brinen LS, Canaves JM, Cambell J, Chiu HJ, Dai X, Deacon AM, DiDonato M, Elsliger MA, Eshagi S, Floyd R, Godzik A, Grittini C, Grzechnik SK, Hampton E, Jaroszewski L, Karlak C, Klock HE, Koesema E, Kovarik JS, Kreusch A, Kuhn P, Lesley SA, Levin I, McMullan D, McPhillips TM, Morse A, Moy K, Ouyang J, Page R, Quijano K, Robb A, Spraggon G, Stevens RC, van den Bedem H, Velasquez J, Vincent J, Wang X, West B, Wolf G, Xu Q, Hodgson KO, Wooley J, and Wilson IA. Crystal structure of a tandem cystathionine-β-synthase (CBS) domain protein (TM0935) from Thermotoga maritima at 1.87A resolution. Proteins 57: 213-217, 2004.
55. Mindell JA, Maduke M, Miller C, and Grigorieff N. Projection structure of a ClC-type chloride channel at 6.5A resolution. Nature 409: 219-223, 2001.
56. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414: 821-827, 2001.
57. Morris RE, Wang J, Blum JR, Flavin T, Murphy MP, Almquist SJ, Chu N, Tam YL, Kaloostian M, Allison AC, and Eugui EM. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 23: 19-25, 1991.
58. Nagai M, Natsumeda Y, Konno Y, Hoffman R, Irino S, and Weber G. Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res 51: 3886-3890, 1991.
59. Nagai M, Natsumeda Y, and Weber G. Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res 52: 258-261, 1992.
60. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, and Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem 265: 5292-5295, 1990.
61. Nimmesgern E, Black J, Futer O, Fulghum JR, Chambers SP, Brummel CL, Raybuck SA, and Sintchak MD. Biochemical analysis of the modular enzyme inosine 5′-monophosphate dehydrogenase. Protein Expr Purif 17: 282-289, 1999.
62. Nozaki T, Shigeta Y, Saito-Nakano Y, Imada M, and Kruger WD. Characterization of transsulfuration and cysteine biosynthetic pathways in the protozoan hemoflagellate, Trypanosoma cruzi. Isolation and molecular characterization of cystathionine β-synthase and serine acetyllransferase from Trypanosoma. J Biol Chem 276: 6516-6523, 2001.
63. Ponting CP. CBS domains in CIC chloride channels implicated in myotonia and nephrolithiasis (kidney stones). J Mol Med 75: 160-163, 1997.
64. Proffitt RT, Pathak VK, Villacorte DG, and Presant CA. Sensitive radiochemical assay for inosine 5′-monophosphate dehydrogenase and determination of activity in murine tumor and tissue extracts. Cancer Res 43: 1620-1623, 1983.
65. Pusch M. Myotonia caused by mutations in the muscle chloride channel gene CLCN1. Hum Mutat 19: 423-434, 2002.
66. Saviane C, Conti F, and Pusch M. The muscle chloride channel ClC-1 has a double-barreled appearance that is differentially affected in dominant and recessive myotonia. J Gen Physiol 113: 457-468, 1999.
67. Schmidt-Rose T and Jentsch TJ. Reconstitution of functional voltage-gated chloride channels from complementary fragments of CLC-1. J Biol Chem 272: 20515-20521, 1997.
68. 2 and COOH terminus of the yeast CLC putative chloride channel Gef1p. J Biol Chem 273: 15110-15118, 1998.
69. Scott JW, Hawley SA, Green KA, Anis M, Stewart G, Scullion GA, Norman DG, and Hardie DG. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 113: 274-284, 2004.
70. Shan X, Dunbrack RL Jr, Christopher SA, and Kruger WD. Mutations in the regulatory domain of cystathionine β-synthase can functionally suppress patient-derived mutations in cis. Hum Mol Genet 10: 635-643, 2001.
71. Shimura K, Okada M, Shiraki H, and Nakagawa I. Dehydrogenase HIMP. Studies on regulatory properties of crude tissue extracts based on an improved assay method. J Biochem (Tokyo) 94: 1595-1603, 1983.
72. Sintchak MD, Fleming MA, Futer O, Ray buck SA, Chambers SP, Caron PR, Murcko MA, and Wilson KP. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85: 921-930, 1996.
73. Snyder FF, Henderson JF, and Cook DA. Inhibition of purine metabolism-computer-assisted analysis of drug effects. Biochem Pharmacol 21: 2351-2357, 1972.
74. Stapleton D, Mitchelhill KI, Gao G, Widmer J, Michell BJ, Teh T, House CM, Fernandez CS, Cox T, Witters LA, and Kemp BE. Mammalian AMP-activated protein kinase subfamily. J Biol Chem 271: 611-614, 1996.
75. Thornton C, Snowden MA, and Carling D. Identification of a novel AMP-activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle. J Biol Chem 273: 12443-12450, 1998.
76. Vanoye CG and George AL Jr. Functional characterization of recombinant human ClC-4 chloride channels in cultured mammalian cells. J Physiol 539: 373-383, 2002.
77. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer Res 43: 3466-3492, 1983.
78. Winder WW and Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol Endocrinol Metab 277: E1-E10, 1999.
79. Zhang R, Evans G, Rotella FJ, Westbrook EM, Beno D, Huberman E, Joachimiak A, and Collart FR. Characteristics and crystal structure of bacterial inosine-5′-monophosphate dehydrogenase. Biochemistry 38: 4691-4700. 1999.